Arixtra
OVERDOSE
There is no known antidote for ARIXTRA (fondaparinux sodium) . Overdose of ARIXTRA (fondaparinux sodium) may lead to hemorrhagic complications. Discontinue treatment and initiate appropriate therapy if bleeding complications associated with overdosage occur.
Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of ARIXTRA (fondaparinux sodium) can increase by 20% during hemodialysis.
CONTRAINDICATIONS
ARIXTRA (fondaparinux sodium) is contraindicated in the following conditions:
- Severe renal impairment (creatinine clearance [CrCl] < 30 mL/min). [See WARNINGS AND PRECAUTIONS and Use in Specific Populations.]
- Active major bleeding.
- Bacterial endocarditis.
- Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium.
- Body weight < 50 kg (venous thromboembolism [VTE] prophylaxis only) [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 4/15/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Arixtra Information
Arixtra - User Reviews
Arixtra User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Arixtra sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
